ECB-ART-50140
Ther Adv Med Oncol
2011 Nov 01;36:279-91. doi: 10.1177/1758834011419002.
Show Gene links
Show Anatomy links
The potential for crizotinib in non-small cell lung cancer: a perspective review.
Bang YJ
.
???displayArticle.abstract???
Tyrosine kinases have a crucial role as key regulators of signaling pathways that influence cell differentiation and growth. Dysregulation of tyrosine kinase-mediated signaling is understood to be an important oncogenic driver. Genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) gene occur in non-small cell lung cancer (NSCLC), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers. Cells with abnormal ALK signaling are sensitive to ALK inhibitors such as crizotinib. This review will highlight the discovery of the fusion between echinoderm microtubule-associated protein-like 4 (EML4) and ALK as an oncogenic driver, recognition of other ALK gene rearrangements in NSCLC, and the confirmation that crizotinib is an effective treatment for patients with ALK-positive NSCLC. Work is underway to further define the role for crizotinib in the treatment of ALK-positive lung cancer and other cancers and to investigate the molecular mechanisms for resistance to ALK inhibition with crizotinib.
???displayArticle.pubmedLink??? 22084642
???displayArticle.pmcLink??? PMC3210468
???displayArticle.link??? Ther Adv Med Oncol
References [+] :
Boland,
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
2009, Pubmed
Boland, Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. 2009, Pubmed
Bustin, Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. 2000, Pubmed
Butrynski, Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. 2010, Pubmed
Camidge, Finding ALK-positive lung cancer: what are we really looking for? 2011, Pubmed
Camidge, Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. 2010, Pubmed
Choi, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. 2010, Pubmed , Echinobase
Christensen, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. 2007, Pubmed
Coffin, Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. 2007, Pubmed
Debelenko, Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. 2011, Pubmed
Drexler, Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. 2000, Pubmed
Gambacorti-Passerini, Crizotinib in anaplastic large-cell lymphoma. 2011, Pubmed
Gascoyne, ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. 2003, Pubmed
Govindan, Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. 2006, Pubmed
Greenlee, Cancer statistics, 2000. 2000, Pubmed
Hirsch, The tissue is the issue: personalized medicine for non-small cell lung cancer. 2010, Pubmed
Horn, EML4-ALK: honing in on a new target in non-small-cell lung cancer. 2009, Pubmed
Ikeda, [Detection of ALK positive pulmonary adenocarcinoma using immunostaining]. 2010, Pubmed
Inamura, EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. 2008, Pubmed , Echinobase
Jazii, Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. 2006, Pubmed
Jänne, Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. 2012, Pubmed
Koh, Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. 2011, Pubmed
Koivunen, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. 2008, Pubmed
Kwak, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010, Pubmed
Lamant, High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. 1996, Pubmed
Langer, The evolving role of histology in the management of advanced non-small-cell lung cancer. 2010, Pubmed
Li, Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. 2004, Pubmed
Li, Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. 2011, Pubmed , Echinobase
Ma, Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. 2003, Pubmed
Maemondo, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. 2010, Pubmed
Mano, Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. 2008, Pubmed , Echinobase
Martelli, EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. 2009, Pubmed , Echinobase
McDermott, Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. 2008, Pubmed
Mitsudomi, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. 2010, Pubmed
Mok, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. 2009, Pubmed
Morris, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. 1994, Pubmed
Mossé, Identification of ALK as a major familial neuroblastoma predisposition gene. 2008, Pubmed
Onciu, ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. 2003, Pubmed
Ouyang, Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). 2003, Pubmed
Paik, Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. 2011, Pubmed
Palmer, Anaplastic lymphoma kinase: signalling in development and disease. 2009, Pubmed , Echinobase
Perner, EML4-ALK fusion lung cancer: a rare acquired event. 2008, Pubmed
Pulford, Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. 1997, Pubmed
Pulford, Anaplastic lymphoma kinase proteins in growth control and cancer. 2004, Pubmed
Riera, Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. 2010, Pubmed
Rikova, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. 2007, Pubmed
Rodig, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. 2009, Pubmed
Rodig, Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. 2010, Pubmed
Sakairi, EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. 2010, Pubmed , Echinobase
Sasaki, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. 2010, Pubmed
Sasaki, The biology and treatment of EML4-ALK non-small cell lung cancer. 2010, Pubmed , Echinobase
Shaw, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009, Pubmed
Shinmura, EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. 2008, Pubmed
Shiota, The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. 1996, Pubmed
Shiota, Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. 1995, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Soda, A mouse model for EML4-ALK-positive lung cancer. 2008, Pubmed
Sun, Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. 2010, Pubmed
Takahashi, Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. 2010, Pubmed , Echinobase
Takeuchi, Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. 2008, Pubmed
Takeuchi, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009, Pubmed
Takeuchi, Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. 2011, Pubmed
Timofeevski, Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. 2009, Pubmed
Tiseo, EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. 2011, Pubmed
Webb, Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. 2009, Pubmed
Wong, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. 2009, Pubmed , Echinobase
Yang, Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. 2005, Pubmed
Yi, Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. 2011, Pubmed
Yoshida, Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. 2011, Pubmed
Zhang, Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. 2010, Pubmed
Zou, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. 2007, Pubmed